Anita van de Munckhof, Mayte Sánchez van Kammen, Katarzyna Krzywicka, Sanjith Aaron, Diana Aguiar de Sousa, Florina Antochi, Antonio Arauz, Miguel A Barboza, Adriana B Conforto, Francesco Dentali, Daniel Galdames Contreras, Xunming Ji, Katarina Jood, Mirjam R Heldner, María Hernández-Pérez, Wayneho Kam, Timothy J Kleinig, Espen S Kristoffersen, Ronen R Leker, Robin Lemmens, Sven Poli, Nilüfer Yeşilot, Mohammad Wasay, Teddy Y Wu, Marcel Arnold, Lia Lucas-Neto, Saskia Middeldorp, Jukka Putaala, Turgut Tatlisumak, José M Ferro, Jonathan M Coutinho
INTRODUCTION: Current guidelines recommend that patients with cerebral venous thrombosis (CVT) should be treated with vitamin K antagonists (VKAs) for 3-12 months. Direct oral anticoagulants (DOACs), however, are increasingly used in clinical practice. An exploratory randomized controlled trial including 120 patients with CVT suggested that the efficacy and safety profile of dabigatran (a DOAC) is similar to VKAs for the treatment of CVT, but large-scale prospective studies from a real-world setting are lacking...
2023: Frontiers in Neurology